Updated Rezatapopt Monotherapy Interim Data From Ongoing PYNNACLE Ph 2 Trial Across Multiple Solid Tumors With a TP53 Y220C Mutation Announced
“We are pleased to share these updated results from the pivotal portion of the ongoing PYNNACLE trial, which continue to enhance our understanding about the potential of rezatapopt to deliver deep and durable responses in patients with limited targeted treatment options. The improvements in overall response rates and median duration of response across all cohorts and specifically in the ovarian cancer cohort are encouraging and further support the potential of rezatapopt to meaningfully impact outcomes for patients with TP53 Y220C mutated advanced tumors,” said Deepika Jalota, Pharm.D., Chief Development Officer of PMV Pharma. “We remain on track to submit an NDA in the first quarter of 2027 for platinum-resistant/refractory ovarian cancer, while continuing to generate additional data to support our broader regulatory strategy.”
Share:
More News
“These data underscore gotistobart’s potential to redefine treatment for patients with hard-to-treat squamous NSCLC whose disease has progressed after initial therapy and who face limited options,” said Prof. Özlem Türeci, M.D., Co-Founder and Chief Medical Officer at BioNTech. “In second- and later lines of treatment, the clinical relevance of novel
“The collaboration with Ratio represents an exciting opportunity to explore the potential of novel radiopharmaceutical approaches designed to address the complexity and heterogeneity of cancer,” said Ben Hickey, President of RayzeBio. “The combination of our respective technologies and complementary development expertise creates a strong foundation for generating a novel differentiated
“We believe these results mark a potentially important step forward in the treatment of EGFR exon 20 insertion mutation-positive non-small cell lung cancer,” said Fabio Benedetti, MD, Global Chief Medical Officer, Taiho Pharmaceutical. “To address the unmet medical needs of patients and their families, we will continue working closely with
“Recent clinical data validated KAT6 as a targetable mechanism in the treatment of HR+/HER2- breast cancer, including those with actionable mutations,” stated Charles Morris, MBChB, MRCP, Chief Medical Officer of Prelude. “Dual KAT6A/B inhibitors, however, demonstrated overlapping toxicities with current backbone therapies that may limit the utility in earlier lines